TransMedics Group (TMDX) Stock Forecast & Price Target

Compare

1,418 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TMDX Analyst Ratings

Moderate Buy

5 Buy

3 Hold

0 Sell

Based on 8 analysts giving stock ratings to

TransMedics

Group

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TMDX Stock 12 Month Forecast

Average Price Target

$117.33

▼(-8.71%Downside)

Based on 8 Wall Street analysts offering 12 month price targets for TransMedics Group in the last 3 months. The average price target is $117.33 with a high forecast of $146.00 and a low forecast of $80.00. The average price target represents a -8.71% change from the last price of $128.53.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"61":"$61","88":"$88","115":"$115","142":"$142","169":"$169"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":146,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$146.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":117.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$117.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$80.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[61,88,115,142,169],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,90.45,94.72307692307693,98.99615384615385,103.26923076923077,107.5423076923077,111.81538461538462,116.08846153846154,120.36153846153846,124.63461538461539,128.90769230769232,133.18076923076922,137.45384615384614,141.72692307692307,{"y":146,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,90.45,92.51769230769231,94.58538461538461,96.65307692307692,98.72076923076924,100.78846153846155,102.85615384615384,104.92384615384616,106.99153846153845,109.05923076923077,111.12692307692308,113.19461538461539,115.26230769230769,{"y":117.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,90.45,89.64615384615385,88.8423076923077,88.03846153846155,87.23461538461538,86.43076923076923,85.62692307692308,84.82307692307693,84.01923076923077,83.21538461538462,82.41153846153847,81.6076923076923,80.80384615384615,{"y":80,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":117.6,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":136.4,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":150.19,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":151.51,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":168.06,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":144.82,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.4,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.14,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.35,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.55,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.32,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.27,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$146.00

Average Price Target$117.33

Lowest Price Target$80.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$142

Buy

10.48%

Upside

Reiterated

05/24/25

The overall stock score of 78 is primarily driven by strong financial performance and bullish technical indicators. The high valuation indicates potential risk, but the positive earnings call outlook and strategic initiatives support future growth prospects. Investors should remain cautious of the high P/E ratio and cash flow challenges.

Josh JenningsTD Cowen

TD Cowen

$130→$146

Buy

13.59%

Upside

Reiterated

05/22/25

TransMedics Group: Buy Rating Affirmed Amid Strategic Positioning and FDA Approval Prospects

William PlovanicCanaccord Genuity

Canaccord Genuity

$104→$129

Buy

0.37%

Upside

Reiterated

05/12/25

Strong Growth in Transplant Market Drives Buy Rating for TransMedics Group

Suraj KaliaOppenheimer

Oppenheimer

$130

Buy

1.14%

Upside

Reiterated

05/09/25

TransMedics Group (TMDX) PT Raised to $130 at OppenheimerOppenheimer analyst Suraj Kalia raised the price target on TransMedics Group (NASDAQ: TMDX) to $130.00 (from $125.00) while maintaining a Outperform rating.

Allen GongJ.P. Morgan

J.P. Morgan

$81→$114

Hold

-11.30%

Downside

Reiterated

05/09/25

TransMedics Group (TMDX) PT Raised to $114 at JPMorganJPMorgan analyst Allen Gong raised the price target on TransMedics Group (NASDAQ: TMDX) to $114.00 (from $81.00) while maintaining a Neutral rating.

Patrick WoodMorgan Stanley

Morgan Stanley

$80

Hold

-37.76%

Downside

Reiterated

05/09/25

TransMedics Group: Strong Performance with Cautious Outlook Amid Competitive and Reimbursement Uncertainties

Michael MatsonNeedham

Needham

―

Hold

―

Reiterated

05/09/25

TransMedics Group: Balancing Strong Q1 Performance with Growth and Margin Concerns

Ryan DanielsWilliam Blair

William Blair

―

Buy

―

Reiterated

05/08/25

TransMedics Group: Strong Financial Performance and Promising Growth Prospects Drive Buy Rating

Matthew O'BrienPiper Sandler

Piper Sandler

$105

Buy

-18.31%

Downside

Reiterated

05/06/25

Piper Sandler Keeps Their Buy Rating on TransMedics Group (TMDX)

Unknown AnalystNephron

Not Ranked

Nephron

$105

Buy

-18.31%

Downside

Initiated

01/06/25

Nephron starts TransMedics Group (TMDX) at BuyNephron initiates coverage on TransMedics Group (NASDAQ: TMDX) with a Buy rating and a price target of $105.00.

David RescottRobert W. Baird

Robert W. Baird

$150→$120

Buy

-6.64%

Downside

Reiterated

12/11/24

TransMedics price target lowered to $120 from $150 at BairdTransMedics price target lowered to $120 from $150 at Baird

George SellersStephens

Stephens

$151→$178

Buy

38.49%

Upside

Reiterated

08/02/24

TransMedics Group (TMDX) PT Raised to $178 at StephensStephens analyst George Sellers raised the price target on TransMedics Group (NASDAQ: TMDX) to $178.00 (from $151.00) while maintaining a Overweight rating.

Unknown AnalystC.L. King

Not Ranked

C.L. King

$161

Buy

25.26%

Upside

Initiated

06/06/24

CL King starts TransMedics Group (TMDX) at BuyCL King initiates coverage on TransMedics Group (NASDAQ: TMDX) with a Buy rating and a price target of $161.00.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$142

Buy

10.48%

Upside

Reiterated

05/24/25

Josh JenningsTD Cowen

TD Cowen

$130→$146

Buy

13.59%

Upside

Reiterated

05/22/25

TransMedics Group: Buy Rating Affirmed Amid Strategic Positioning and FDA Approval Prospects

William PlovanicCanaccord Genuity

Canaccord Genuity

$104→$129

Buy

0.37%

Upside

Reiterated

05/12/25

Strong Growth in Transplant Market Drives Buy Rating for TransMedics Group

Suraj KaliaOppenheimer

Oppenheimer

$130

Buy

1.14%

Upside

Reiterated

05/09/25

Allen GongJ.P. Morgan

J.P. Morgan

$81→$114

Hold

-11.30%

Downside

Reiterated

05/09/25

Patrick WoodMorgan Stanley

Morgan Stanley

$80

Hold

-37.76%

Downside

Reiterated

05/09/25

TransMedics Group: Strong Performance with Cautious Outlook Amid Competitive and Reimbursement Uncertainties

Michael MatsonNeedham

Needham

―

Hold

―

Reiterated

05/09/25

TransMedics Group: Balancing Strong Q1 Performance with Growth and Margin Concerns

Ryan DanielsWilliam Blair

William Blair

―

Buy

―

Reiterated

05/08/25

TransMedics Group: Strong Financial Performance and Promising Growth Prospects Drive Buy Rating

Matthew O'BrienPiper Sandler

Piper Sandler

$105

Buy

-18.31%

Downside

Reiterated

05/06/25

Piper Sandler Keeps Their Buy Rating on TransMedics Group (TMDX)

Unknown AnalystNephron

Not Ranked

Nephron

$105

Buy

-18.31%

Downside

Initiated

01/06/25

Nephron starts TransMedics Group (TMDX) at BuyNephron initiates coverage on TransMedics Group (NASDAQ: TMDX) with a Buy rating and a price target of $105.00.

David RescottRobert W. Baird

Robert W. Baird

$150→$120

Buy

-6.64%

Downside

Reiterated

12/11/24

TransMedics price target lowered to $120 from $150 at BairdTransMedics price target lowered to $120 from $150 at Baird

George SellersStephens

Stephens

$151→$178

Buy

38.49%

Upside

Reiterated

08/02/24

Unknown AnalystC.L. King

Not Ranked

C.L. King

$161

Buy

25.26%

Upside

Initiated

06/06/24

CL King starts TransMedics Group (TMDX) at BuyCL King initiates coverage on TransMedics Group (NASDAQ: TMDX) with a Buy rating and a price target of $161.00.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering TransMedics Group

1 Month

xxx

Success Rate

16/26 ratings generated profit

Average Return

+6.80%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 61.54% of your transactions generating a profit, with an average return of +6.80% per trade.

3 Months

xxx

Success Rate

17/26 ratings generated profit

Average Return

+19.13%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 65.38% of your transactions generating a profit, with an average return of +19.13% per trade.

1 Year

William PlovanicCanaccord Genuity

Success Rate

20/26 ratings generated profit

Average Return

+62.14%

reiterated a buy rating 17 days ago

Copying William Plovanic's trades and holding each position for 1 Year would result in 76.92% of your transactions generating a profit, with an average return of +62.14% per trade.

2 Years

xxx

Success Rate

24/26 ratings generated profit

Average Return

+118.88%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 92.31% of your transactions generating a profit, with an average return of +118.88% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TMDX Analyst Recommendation Trends

Rating

Jan 25

Feb 25

Mar 25

Apr 25

May 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TMDX has received 14 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. TMDX average Analyst price target in the past 3 months is 117.33.

Each month's total comprises the sum of three months' worth of ratings.

TMDX Financial Forecast

TMDX Earnings Forecast

Next quarter’s earnings estimate for TMDX is $0.45 with a range of $0.34 to $0.59. The previous quarter’s EPS was $0.70. TMDX beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.23% of the time in the same period. In the last calendar year TMDX has Outperformed its overall industry.

TMDX Sales Forecast

Next quarter’s sales forecast for TMDX is $146.74M with a range of $144.00M to $150.01M. The previous quarter’s sales results were $143.54M. TMDX beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.59% of the time in the same period. In the last calendar year TMDX has Outperformed its overall industry.

TMDX Stock Forecast FAQ

What is TMDX’s average 12-month price target, according to analysts?

Based on analyst ratings, TransMedics Group Inc’s 12-month average price target is 117.33.

What is TMDX’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for TMDX, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TMDX a Buy, Sell or Hold?

TransMedics Group Inc has a consensus rating of Moderate Buy which is based on 5 buy ratings, 3 hold ratings and 0 sell ratings.

What is TransMedics Group Inc’s price target?

The average price target for TransMedics Group Inc is 117.33. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $146.00 ,the lowest forecast is $80.00. The average price target represents -8.71% Decrease from the current price of $128.53.

What do analysts say about TransMedics Group Inc?

TransMedics Group Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of TMDX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

TransMedics Group (TMDX) Stock Forecast & Price Target

TMDX Analyst Ratings

TMDX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering TransMedics Group

TMDX Analyst Recommendation Trends

TMDX Financial Forecast

TMDX Earnings Forecast

TMDX Sales Forecast

TMDX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts